[
  {
    "ts": null,
    "headline": "Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago.",
    "url": "https://finnhub.io/api/news?id=ce574d7401cb1d3ac9ccd8c58e39c632d42a4d1dca67349d2255f10d3821d432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747947900,
      "headline": "Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
      "id": 134658388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and Verzenio® (abemaciclib; a CDK4/6 inhibitor) will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago.",
      "url": "https://finnhub.io/api/news?id=ce574d7401cb1d3ac9ccd8c58e39c632d42a4d1dca67349d2255f10d3821d432"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).",
    "url": "https://finnhub.io/api/news?id=7175f9b5943a38d0306f0a5f41b12261a5475d803bf608fcadf6c19abc5e5651",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747946040,
      "headline": "Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen",
      "id": 134658389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).",
      "url": "https://finnhub.io/api/news?id=7175f9b5943a38d0306f0a5f41b12261a5475d803bf608fcadf6c19abc5e5651"
    }
  },
  {
    "ts": null,
    "headline": "Cigna takes different approach with GLP-1s, more favorable for Eli Lilly",
    "summary": "Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly (NYSE:LLY) than rival models.",
    "url": "https://finnhub.io/api/news?id=d67682388ad2176d0f449dcd0d68d9f092205709bca8f8e3f9904916ac8c844f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747937399,
      "headline": "Cigna takes different approach with GLP-1s, more favorable for Eli Lilly",
      "id": 134658390,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Cigna’s Evernorth has introduced a new pharmacy benefit that caps out-of-pocket costs for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly (NYSE:LLY) than rival models.",
      "url": "https://finnhub.io/api/news?id=d67682388ad2176d0f449dcd0d68d9f092205709bca8f8e3f9904916ac8c844f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Wins Approval For Alzheimer's Drug Kisunla In Australia",
    "summary": "Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer's treatment, potentially adding positive investor sentiment. This development is significant given the growing Alzheimer's population in Australia. While the broader market faced a 1.1% decline amid fiscal policy concerns, Eli Lilly’s news likely provided a counterbalancing effect, helping it...",
    "url": "https://finnhub.io/api/news?id=96cb8513776d1ee748bb42d6ef65a90ab28d7c4826f5e662e51fb0a7d8465c2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747935009,
      "headline": "Eli Lilly (NYSE:LLY) Wins Approval For Alzheimer's Drug Kisunla In Australia",
      "id": 134658391,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian Therapeutic Goods Administration's approval of Kisunla, its novel Alzheimer's treatment, potentially adding positive investor sentiment. This development is significant given the growing Alzheimer's population in Australia. While the broader market faced a 1.1% decline amid fiscal policy concerns, Eli Lilly’s news likely provided a counterbalancing effect, helping it...",
      "url": "https://finnhub.io/api/news?id=96cb8513776d1ee748bb42d6ef65a90ab28d7c4826f5e662e51fb0a7d8465c2d"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks",
    "summary": "Widely used GLP-1 drugs for type 2diabetes such as Novo Nordisk's Ozempic may modestlyreduce the risk of obesity-related cancers, especiallycolorectal cancer, according to data released on Thursday...",
    "url": "https://finnhub.io/api/news?id=ee48ec584bca285a9b9f5f7996e98c7672ba8b45a27b0f8b67c93fbcbbccbf3b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747934772,
      "headline": "GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks",
      "id": 134653583,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Widely used GLP-1 drugs for type 2diabetes such as Novo Nordisk's Ozempic may modestlyreduce the risk of obesity-related cancers, especiallycolorectal cancer, according to data released on Thursday...",
      "url": "https://finnhub.io/api/news?id=ee48ec584bca285a9b9f5f7996e98c7672ba8b45a27b0f8b67c93fbcbbccbf3b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=07dca42b1a941e74fcb3ffa425bc8033bd7b94e62bed934e2d21b88b681ea906",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747931460,
      "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "id": 134662224,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=07dca42b1a941e74fcb3ffa425bc8033bd7b94e62bed934e2d21b88b681ea906"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk battles Wegovy copycats through discounted prices, legal threats",
    "summary": "Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.",
    "url": "https://finnhub.io/api/news?id=2a56eea9aec463b4ef1d7323763201ad1796e83a905c695884f22cebe63736c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747922498,
      "headline": "Novo Nordisk battles Wegovy copycats through discounted prices, legal threats",
      "id": 134658392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.",
      "url": "https://finnhub.io/api/news?id=2a56eea9aec463b4ef1d7323763201ad1796e83a905c695884f22cebe63736c4"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Say Checkmate to Novo Nordisk?",
    "summary": "A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product.  Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger.  Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.",
    "url": "https://finnhub.io/api/news?id=ce4b71bc2d068bca6b873dea0c30c289798009f6c6d128a404cbcf6914aacc01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747915200,
      "headline": "Did Eli Lilly Just Say Checkmate to Novo Nordisk?",
      "id": 134650234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product.  Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest challenger.  Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.",
      "url": "https://finnhub.io/api/news?id=ce4b71bc2d068bca6b873dea0c30c289798009f6c6d128a404cbcf6914aacc01"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy and Zepbound costs capped at $200 in new Evernorth programme",
    "summary": "The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US.",
    "url": "https://finnhub.io/api/news?id=fa335c2262947c17a39f17722f0057a6115e39dd33709ac359afe7a1b39f5f23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747914991,
      "headline": "Wegovy and Zepbound costs capped at $200 in new Evernorth programme",
      "id": 134648120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US.",
      "url": "https://finnhub.io/api/news?id=fa335c2262947c17a39f17722f0057a6115e39dd33709ac359afe7a1b39f5f23"
    }
  },
  {
    "ts": null,
    "headline": "Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays",
    "summary": "The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for Evernorth’s employer and health plan clients.",
    "url": "https://finnhub.io/api/news?id=e7f3077a620d477d06fd9151b49ab1e608f947298b240a635a91a816e0539ed9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747912476,
      "headline": "Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays",
      "id": 134658395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for Evernorth’s employer and health plan clients.",
      "url": "https://finnhub.io/api/news?id=e7f3077a620d477d06fd9151b49ab1e608f947298b240a635a91a816e0539ed9"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia",
    "summary": "The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.",
    "url": "https://finnhub.io/api/news?id=d797ae83964758959cd1078a9608f23d2ffd9a1d0646086fdf6928668fab99bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747912201,
      "headline": "Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia",
      "id": 134647906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.",
      "url": "https://finnhub.io/api/news?id=d797ae83964758959cd1078a9608f23d2ffd9a1d0646086fdf6928668fab99bc"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Kisunla receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease",
    "summary": "INDIANAPOLIS - Eli Lilly and Company announced that the Australian Therapeutic Goods Administration has granted marketing authorization for Kisunla , an injection for intravenous infusion every four...",
    "url": "https://finnhub.io/api/news?id=7c98b89ac9c203230f0546e297ea26854172eb5e7e8b482e28e6911f626328d6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747911309,
      "headline": "Lilly's Kisunla receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease",
      "id": 134651029,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company announced that the Australian Therapeutic Goods Administration has granted marketing authorization for Kisunla , an injection for intravenous infusion every four...",
      "url": "https://finnhub.io/api/news?id=7c98b89ac9c203230f0546e297ea26854172eb5e7e8b482e28e6911f626328d6"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Global Opportunities Fund Q1 2025 Commentary",
    "summary": "The Artisan Global Opportunities Fund portfolio generated negative absolute returns for Q1 of 2025. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f6d78cb14e7f38f45300260494bcda66c2c15327813613cd55ed2f8b93d5b2a4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747899600,
      "headline": "Artisan Global Opportunities Fund Q1 2025 Commentary",
      "id": 134648301,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2174795498/image_2174795498.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Artisan Global Opportunities Fund portfolio generated negative absolute returns for Q1 of 2025. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=f6d78cb14e7f38f45300260494bcda66c2c15327813613cd55ed2f8b93d5b2a4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Alzheimer's treatment approved in Australia",
    "summary": "US pharmaceutical company Eli Lilly has received marketing approval in Australia for Kisunla , a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease. This is according to...",
    "url": "https://finnhub.io/api/news?id=efa641e2017cbc800c38ff55f438d196d14ec313f168c2c311fb1675c503257b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747876030,
      "headline": "Eli Lilly's Alzheimer's treatment approved in Australia",
      "id": 134632197,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "US pharmaceutical company Eli Lilly has received marketing approval in Australia for Kisunla , a treatment for mild cognitive impairment and mild dementia in Alzheimer's disease. This is according to...",
      "url": "https://finnhub.io/api/news?id=efa641e2017cbc800c38ff55f438d196d14ec313f168c2c311fb1675c503257b"
    }
  },
  {
    "ts": null,
    "headline": "VHT Looks Attractive, And Risks May Be Overestimated",
    "summary": "Healthcare stocks face challenges from political risks, but opportunities arise for long-term investors.",
    "url": "https://finnhub.io/api/news?id=e996fd0066428181f76961d29b52c5170ddcde49602498c1ddfe41888a7d72d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747873523,
      "headline": "VHT Looks Attractive, And Risks May Be Overestimated",
      "id": 134632000,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1317799665/image_1317799665.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Healthcare stocks face challenges from political risks, but opportunities arise for long-term investors.",
      "url": "https://finnhub.io/api/news?id=e996fd0066428181f76961d29b52c5170ddcde49602498c1ddfe41888a7d72d6"
    }
  }
]